HUTCHMED wins approval for ATLED cancer treatment
HUTCHMED (NASDAQ:HCM) received conditional approval from China’s National Medical Products Administration for ATLED® (fanregratinib, HMPL-453), an oral FGFR 1/2/3 inhibitor for certain adults with advanced intrahepatic cholangiocarcinoma.










